Kura Oncology-backed Caspian advances KO-7246 menin inhibitor toward first-in-human diabetes trials

By Public Technologies
  • Kura Oncology highlighted new preclinical results for KO-7246, positioning it as a menin inhibitor aimed at restoring insulin-producing beta-cell function.
  • Data were presented at the European Association for the Study of Diabetes meeting, with an investor webcast scheduled for Oct. 13, 2026.
  • Studies showed durable glycemic control with effects that persisted after dosing ended, supporting a potential disease-modifying profile in diabetes models.
  • Results also indicated selective beta-cell regeneration in human islets, with potential to complement GLP-1 therapy based on combination findings.
  • Kura’s Caspian Therapeutics unit is advancing KO-7246 through IND-enabling work toward initial clinical evaluation.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290515PRIMZONEFULLFEED9835632) on September 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.